Observational studyPediatric nephrology (Berlin, Germany)2026
Exploring urinary allantoin and adenosine in pediatric autosomal dominant polycystic kidney disease: no clear association with disease severity.
Observational study in Pediatric nephrology (Berlin, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
backgroundProteinuria and hypertension are commonly observed in children with autosomal dominant polycystic kidney disease (ADPKD), but reliable non-invasive biochemical markers for early disease activity or progression in pediatric ADPKD are lacking. Allantoin and the allantoin/uric acid ratio are recognized oxidative stress biomarkers in chronic kidney disease and may hold potential for early disease monitoring in ADPKD.
methodsIn this observational study, 34 patients with genotyped PKD1-ADPKD under 18 years with preserved kidney function were compared to 31 healthy controls. Urinary allantoin and adenosine were measured using a validated high-performance liquid chromatography (HPLC)-UV method. Associations with established markers of disease progression, including estimated glomerular filtration rate, total kidney volume (TKV), and the Leuven Imaging Classification (LIC) score, were assessed.
resultsUrinary allantoin, adenosine and the urinary allantoin/uric acid ratio did not differ significantly between patients and controls. In the ADPKD cohort, significant negative correlations were found between urinary allantoin and TKV (r = -0.49 P = 0.0043) and between urinary allantoin/uric acid ratio and TKV (r = -0.41 P = 0.0228). No correlations were observed between urinary allantoin and LIC score. Across all participants, urinary allantoin levels negatively correlated with age (r = -0.54 P = 0.0015; r = -0.74 P = 8.75e-007).
conclusionsAlthough urinary allantoin, adenosine, and the allantoin/uric acid ratio were comparable between pediatric patients with ADPKD and controls, inverse associations between allantoin and TKV were observed between the groups. However, the lack of correlation with LIC score and the negative correlation with age limit its potential as a marker in pediatric ADPKD.
Indexed as
Identifiers
42287314What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.